Testing a new lung cancer drug alone or combined with chemotherapy

Plain-English translation of NCT05334277 on ClinicalTrials.gov ↗ · Source last updated August 2022 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called to treat advanced non-small cell lung cancer in patients whose cancer has a specific genetic change (an EGFR mutation). After an initial 3-week test period, patients whose cancer still shows signs of growth will be randomly assigned to receive the medication alone, or combined with chemotherapy, or combined with chemotherapy and another drug called bevacizumab.

For patients with this type of lung cancer, doctors want to know whether combining this medication with chemotherapy works better than using it by itself, and whether adding a third drug improves outcomes even further.

Do you qualify?

You likely qualify if…

you are at least 18 years old with a life expectancy of at least 12 weeks
you have been diagnosed with advanced non-small cell lung cancer that cannot be treated with surgery or radiation
your cancer has an EGFR mutation (a specific genetic change) confirmed through a blood test
you have not received any previous treatment with EGFR-targeting drugs
you are willing to take daily oral medication and attend approximately 9 study visits

You likely don't qualify if…

you have squamous cell lung cancer (a different type)
you have a history of allergic reactions to the study medication or similar drugs
you have received prior EGFR-targeting drugs or other recent cancer treatments
you are taking certain medications that strongly interact with the study drug
you are pregnant, breastfeeding, or unwilling to use contraception during the study

What participation looks like

You will start by taking the new medication daily for 3 weeks to see how your cancer responds. Then, based on your response, you'll be randomly assigned to one of three treatment groups: continuing the medication alone, or combining it with chemotherapy given every 3 weeks, or combining it with both chemotherapy and bevacizumab. Throughout the study, you'll attend about 9 visits lasting 2–6 hours each, where doctors will check your health and run tests to see how well the treatment is working.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(26 sites)

China

The First Hospital of Jilin University, Changchun

Sichuan Provincial People's Hospital, Chengdu

Dongguan People's Hospital, Dongguan

Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang People's hospital, Dongyang

The First People's Hospital of Foshan, Foshan